Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats

Cook,Matthew  T.; Mafuvadze,Benford; Besch-Williford,Cynthia; Ellersieck,Mark  R.; Goyette,Sandy; Hyder,Salman  M.

doi:10.3892/or.2015.4431

Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats

Authors:
- Matthew T. Cook
- Benford Mafuvadze
- Cynthia Besch-Williford
- Mark R. Ellersieck
- Sandy Goyette
- Salman M. Hyder
View Affiliations

Affiliations: Department of Biomedical Sciences and Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65211, USA, IDEXX BioResearch, Columbia, MO 65202, USA, Agriculture Experiment Station, University of Missouri, Columbia, MO 65211, USA
Published online on: November 17, 2015 https://doi.org/10.3892/or.2015.4431
Pages: 825-832

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postmenopausal women undergoing hormone-replacement therapy containing both progestins and estrogens are at an increased risk of developing breast cancer compared with women taking estrogen alone. We recently demonstrated that medroxyprogesterone acetate, a progestin commonly used for hormone-replacement therapy, accelerates development of mammary carcinogenesis in 7,12-dimethylbenz(a)anthracene‑treated Sprague-Dawley rats. Synthetic antiprogestins used to block the deleterious effects of progestins, are themselves associated with toxic side-effects. In order to circumvent this, we used the aforementioned model to identify less toxic natural compounds that may prevent the development of progestin-accelerated tumors. Luteolin, a naturally-occurring flavonoid commonly found in fruits and vegetables, has previously been shown to possess anticancer properties. In our studies, both low (1 mg/kg) and high (25 mg/kg) doses of luteolin significantly suppressed progestin-dependent increases in tumor incidence, while increasing tumor latency and reducing the occurrence of large (>300 mm3) mammary tumors. However, an intermediate dose of luteolin (10 mg/kg), while suppressing the development of large tumors, did not affect either tumor incidence or latency. Immunohistochemical analysis of tumor tissues revealed that all concentrations of luteolin (1, 10, and 25 mg/kg) significantly reduced levels of VEGF within tumors. The suppressive effects of luteolin on tumor incidence and volume, together with its ability to reduce VEGF and blood vessels, persisted even after treatment was terminated. This suggests that luteolin possesses anti‑angiogenic properties which could mechanistically explain its capacity to control tumor progression. Thus luteolin may be a valuable, non-toxic, naturally-occurring anticancer compound which may potentially be used to combat progestin-accelerated mammary tumors.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al WHI Investigators: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA. 289:3243–3253. 2003. View Article : Google Scholar : PubMed/NCBI
3	Beral V; Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362:419–427. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:321–333. 2002. View Article : Google Scholar : PubMed/NCBI
5	Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N and von Schoultz E: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 49:52–59. 2013. View Article : Google Scholar
6	Horn LC, Schnurrbusch U, Bilek K, Hentschel B and Einenkel J: Risk of progression in complex and atypical endometrial hyperplasia: Clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 14:348–353. 2004. View Article : Google Scholar : PubMed/NCBI
7	Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC and Mack TM: Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 89:1110–1116. 1997. View Article : Google Scholar : PubMed/NCBI
8	Brisken C: Progesterone signalling in breast cancer: A neglected hormone coming into the limelight. Nat Rev Cancer. 13:385–396. 2013. View Article : Google Scholar : PubMed/NCBI
9	Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D and Dougall WC: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 468:103–107. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hyder SM, Murthy L and Stancel GM: Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 58:392–395. 1998.PubMed/NCBI
11	Liang Y, Besch-Williford C, Brekken RA and Hyder SM: Progestin-dependent progression of human breast tumor xenografts: A novel model for evaluating antitumor therapeutics. Cancer Res. 67:9929–9936. 2007. View Article : Google Scholar : PubMed/NCBI
12	Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR and Hyder SM: Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause. 17:1040–1047. 2010. View Article : Google Scholar : PubMed/NCBI
13	Liang Y, Wu J, Stancel GM and Hyder SM: p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol. 93:173–182. 2005. View Article : Google Scholar : PubMed/NCBI
14	Liang Y and Hyder SM: Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: Paracrine and autocrine effects. Endocrinology. 146:3632–3641. 2005. View Article : Google Scholar : PubMed/NCBI
15	Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD and Khokha R: Progesterone induces adult mammary stem cell expansion. Nature. 465:803–807. 2010. View Article : Google Scholar : PubMed/NCBI
16	Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, et al: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 468:98–102. 2010. View Article : Google Scholar : PubMed/NCBI
17	Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A and Hyder SM: Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clin Cancer Res. 12:4062–4071. 2006. View Article : Google Scholar : PubMed/NCBI
18	Benakanakere I, Besch-Williford C, Carroll CE and Hyder SM: Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res (Phila). 3:1157–1167. 2010. View Article : Google Scholar
19	Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR and Hyder SM: Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a) anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res (Phila). 4:1316–1324. 2011. View Article : Google Scholar
20	Mafuvadze B, Liang Y, Besch-Williford C, Zhang X and Hyder SM: Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer. 3:160–171. 2012. View Article : Google Scholar : PubMed/NCBI
21	Mafuvadze B, Cook M, Xu Z, Besch-Williford CL and Hyder SM: Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced breast cancer model. Nutr Cancer. 65:1184–1191. 2013. View Article : Google Scholar : PubMed/NCBI
22	Lin Y, Shi R, Wang X and Shen HM: Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
23	López-Lázaro M: Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 9:31–59. 2009. View Article : Google Scholar : PubMed/NCBI
24	Seelinger G, Merfort I, Wölfle U and Schempp CM: Anti-carcinogenic effects of the flavonoid luteolin. Molecules. 13:2628–2651. 2008. View Article : Google Scholar : PubMed/NCBI
25	Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C and Fotsis T: Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res. 64:7936–7946. 2004. View Article : Google Scholar : PubMed/NCBI
26	Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, et al: Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One. 7:e522792012. View Article : Google Scholar
27	Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M and Sata M: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids. Cancer Res. 66:4826–4834. 2006. View Article : Google Scholar : PubMed/NCBI
28	Luo H, Jiang BH, King SM and Chen YC: Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr Cancer. 60:800–809. 2008. View Article : Google Scholar : PubMed/NCBI
29	Nordeen SK, Bona BJ, Jones DN, Lambert JR and Jackson TA: Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin. Horm Cancer. 4:293–300. 2013. View Article : Google Scholar : PubMed/NCBI
30	Fang J, Zhou Q, Shi XL and Jiang BH: Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis. 28:713–723. 2007. View Article : Google Scholar
31	Zhou Q, Yan B, Hu X, Li XB, Zhang J and Fang J: Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther. 8:1684–1691. 2009. View Article : Google Scholar : PubMed/NCBI
32	Samy RP, Gopalakrishnakone P and Ignacimuthu S: Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a) anthracene-induced mammary tumors in rats. Chem Biol Interact. 164:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
33	Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, Teixeira-Guedes C, Soares-Maia R, da Costa RG, Colaço B, Pires MJ, Colaço J, Ferreira R, et al: Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim (NY). 42:217–224. 2013. View Article : Google Scholar
34	Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
35	Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH, Shioda T, Soto AM, vom Saal FS, Welshons WV, et al: Hormones and endocrine-disrupting chemicals: Low-dose effects and nonmonotonic dose responses. Endocr Rev. 33:378–455. 2012. View Article : Google Scholar : PubMed/NCBI
36	Markaverich BM, Shoulars K and Rodriguez MA: Luteolin regulation of estrogen signaling and cell cycle pathway genes in MCF-7 human breast cancer cells. Int J Biomed Sci. 7:101–111. 2011.PubMed/NCBI
37	Le Bail JC, Varnat F, Nicolas JC and Habrioux G: Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett. 130:209–216. 1998. View Article : Google Scholar : PubMed/NCBI
38	Zand RSR, Jenkins DJ and Diamandis EP: Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat. 62:35–49. 2000. View Article : Google Scholar : PubMed/NCBI
39	Carroll CE, Liang Y, Benakanakere I, Besch-Williford C and Hyder SM: The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development. Int J Oncol. 42:179–187. 2013.
40	Knutson TP and Lange CA: Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther. 142:114–125. 2014. View Article : Google Scholar :
41	Hyder SM, Chiappetta C and Stancel GM: Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer. 92:469–473. 2001. View Article : Google Scholar : PubMed/NCBI
42	Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA and Richer JK: Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 32:2555–2564. 2013. View Article : Google Scholar
43	Horwitz KB, Dye WW, Harrell JC, Kabos P and Sartorius CA: Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA. 105:5774–5779. 2008. View Article : Google Scholar : PubMed/NCBI
44	Löscher W, Mevissen M and Häussler B: Seasonal influence on 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis in Sprague-Dawley rats under controlled laboratory conditions. Pharmacol Toxicol. 81:265–270. 1997.